Lisata Therapeutics
LSTA
23 hedge funds and large institutions have $1.8M invested in Lisata Therapeutics in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
5% more funds holding
Funds holding: 22 → 23 (+1)
3.01% more ownership
Funds ownership: 6.02% → 9.03% (+3%)
17% less capital invested
Capital invested by funds: $2.17M → $1.8M (-$379K)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$37K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$18.2K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.86K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4.43K |
| 5 |
Morgan Stanley
New York
|
+$488 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$32.3K |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$2.63K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$1.28K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$609 |
| 5 |
IA
IFP Advisors
Tampa,
Florida
|
-$418 |
LSTA Hedge Fund Activity: Q4 2022 in Review
23 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q4 2022, worth a combined $1.8M — down 17% from $2.17M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new LSTA positions and 1 closed out — a net gain of 2 holders — while 6 added to existing stakes and 8 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $37K. The largest seller was Renaissance Technologies, cutting an estimated $32.3K.
- 23 institutional investors held Lisata Therapeutics (LSTA) as of Q4 2022, up from 22 in Q3 2022.
- Funds reported $1.8M of Lisata Therapeutics stock for Q4 2022, down 17% quarter-over-quarter.
- 3 funds opened new Lisata Therapeutics positions in Q4 2022 and 1 closed out, a net change of +2 holders.
- The largest Lisata Therapeutics buyer in Q4 2022 was Citadel Advisors, an estimated $37K added.
- The largest Lisata Therapeutics seller in Q4 2022 was Renaissance Technologies, an estimated $32.3K sold.
Based on aggregated 13F filings for Q4 2022.